These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11348705)

  • 21. Antibodies against a multiple-peptide conjugate comprising chemically modified human immunodeficiency virus type-1 functional Tat peptides inhibit infection.
    Devadas K; Boykins RA; Hewlett IK; Wood OL; Clouse KA; Yamada KM; Dhawan S
    Peptides; 2007 Mar; 28(3):496-504. PubMed ID: 17188401
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human immunodeficiency virus type 1 Tat activity in human neuronal cells: uptake and trans-activation.
    Kolson DL; Collman R; Hrin R; Balliet JW; Laughlin M; McGann KA; Debouck C; Gonzalez-Scarano F
    J Gen Virol; 1994 Aug; 75 ( Pt 8)():1927-34. PubMed ID: 8046394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Tat subunit vaccine confers protective immunity against the immune-modulating activity of the human immunodeficiency virus type-1 Tat protein in mice.
    Agwale SM; Shata MT; Reitz MS; Kalyanaraman VS; Gallo RC; Popovic M; Hone DM
    Proc Natl Acad Sci U S A; 2002 Jul; 99(15):10037-41. PubMed ID: 12096189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Jembrana disease virus Tat can regulate human immunodeficiency virus (HIV) long terminal repeat-directed gene expression and can substitute for HIV Tat in viral replication.
    Chen H; He J; Fong S; Wilcox G; Wood C
    J Virol; 2000 Mar; 74(6):2703-13. PubMed ID: 10684286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A non-proteolytic role for ubiquitin in Tat-mediated transactivation of the HIV-1 promoter.
    Brès V; Kiernan RE; Linares LK; Chable-Bessia C; Plechakova O; Tréand C; Emiliani S; Peloponese JM; Jeang KT; Coux O; Scheffner M; Benkirane M
    Nat Cell Biol; 2003 Aug; 5(8):754-61. PubMed ID: 12883554
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of intra- and extra-cellular Tat function and HIV expression by pertussis toxin B-oligomer.
    Rizzi C; Alfano M; Bugatti A; Camozzi M; Poli G; Rusnati M
    Eur J Immunol; 2004 Feb; 34(2):530-6. PubMed ID: 14768058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reconstruction and function of ancestral center-of-tree human immunodeficiency virus type 1 proteins.
    Rolland M; Jensen MA; Nickle DC; Yan J; Learn GH; Heath L; Weiner D; Mullins JI
    J Virol; 2007 Aug; 81(16):8507-14. PubMed ID: 17537854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brain-derived human immunodeficiency virus-1 Tat exerts differential effects on LTR transactivation and neuroimmune activation.
    Boven LA; Noorbakhsh F; Bouma G; van der Zee R; Vargas DL; Pardo C; McArthur JC; Nottet HS; Power C
    J Neurovirol; 2007 Apr; 13(2):173-84. PubMed ID: 17505986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preparative scale culture of Escherichia coli cells expressing the human immunodeficiency virus type 1 Tat protein.
    McKenna MC; Muchardt C; Gaynor R; Eisenberg D
    Protein Expr Purif; 1994 Apr; 5(2):105-11. PubMed ID: 8054841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel chimeric Rev, Tat, and Nef (Retanef) antigen as a component of an SIV/HIV vaccine.
    Hel Z; Johnson JM; Tryniszewska E; Tsai WP; Harrod R; Fullen J; Tartaglia J; Franchini G
    Vaccine; 2002 Aug; 20(25-26):3171-86. PubMed ID: 12163269
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A DNA HIV-1 vaccine based on a fusion gene expressing non-structural and structural genes of consensus sequence of the A-C subtypes and the ancestor sequence of the F-H subtypes. Preclinical and clinical studies.
    Krohn K; Stanescu I; Blazevic V; Vesikari T; Ranki A; Ustav M
    Microbes Infect; 2005 Nov; 7(14):1405-13. PubMed ID: 16257560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody to HIV-1 Tat protein, a key molecule in HIV-1 pathogenesis. A brief review.
    Re MC; Gibellini D; Vitone F; La Placa M
    New Microbiol; 2001 Apr; 24(2):197-205. PubMed ID: 11346305
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tat-induced lesions in transgenic mice do not correlate with the HIV-1 LTR transactivation.
    Fergelot P; Molina T; Blanchet P; Grimber G; Duquenne O; Couton D; Zider A; Briand P; Cavard C
    C R Acad Sci III; 1995 Mar; 318(3):329-37. PubMed ID: 7788501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Upregulation of urokinase-type plasminogen activator by endogenous and exogenous HIV-1 Tat protein in tumour cell lines derived from BK virus/tat-transgenic mice.
    Rusnati M; Coltrini D; Campioni D; Tanghetti E; Corallini A; Barbanti-Brodano G; Giuliani R; Gibellini D; Presta M
    AIDS; 1997 May; 11(6):727-36. PubMed ID: 9143604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of alternatively spliced human immunodeficiency virus type-1 mRNA species, one of which encodes a novel tat-env fusion protein.
    Furtado MR; Balachandran R; Gupta P; Wolinsky SM
    Virology; 1991 Nov; 185(1):258-70. PubMed ID: 1926777
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New human gene encoding a positive modulator of HIV Tat-mediated transactivation.
    Shibuya H; Irie K; Ninomiya-Tsuji J; Goebl M; Taniguchi T; Matsumoto K
    Nature; 1992 Jun; 357(6380):700-2. PubMed ID: 1377363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunization with low doses of HIV-1 tat DNA delivered by novel cationic block copolymers induces CTL responses against Tat.
    Caputo A; Gavioli R; Altavilla G; Brocca-Cofano E; Boarini C; Betti M; Castaldello A; Lorenzini F; Micheletti F; Cafaro A; Sparnacci K; Laus M; Tondelli L; Ensoli B
    Vaccine; 2003 Mar; 21(11-12):1103-11. PubMed ID: 12559787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.
    Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C
    J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intercellular traffic of human immunodeficiency virus type 1 transactivator protein defined by monoclonal antibodies.
    Demirhan I; Chandra A; Hasselmayer O; Chandra P
    FEBS Lett; 1999 Feb; 445(1):53-6. PubMed ID: 10069373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exon2 of HIV-2 Tat contributes to transactivation of the HIV-2 LTR by increasing binding affinity to HIV-2 TAR RNA.
    Rhim H; Rice AP
    Nucleic Acids Res; 1994 Oct; 22(21):4405-13. PubMed ID: 7971271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.